34396529 34130693 30724873 29912573 34998036 23973932 26660688 23238855 24777953 26049666 29693586 33631143 33673227 29404483 27301803 27422790 33132502 27063276 29856820 25847730 31425963 29279271 35537279 28638584 27157992 32924526 31779112 2705323 - Search Results

Year	Number of Results
2012	4
2013	13
2014	20
2015	18
2016	28
2017	21
2018	22
2019	18
2020	12
2021	15
2022	8

1

Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases.

Sousa L, Guarda M, Meneses MJ, Macedo MP, Vicente Miranda H. Sousa L, et al. J Pathol. 2021 Dec;255(4):346-361. doi: 10.1002/path.5777. Epub 2021 Sep 17. J Pathol. 2021. PMID: 34396529 Review.

2

Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching.

Zheng X, Cao C, He Y, Wang X, Wu J, Hu H. Zheng X, et al. Lipids Health Dis. 2021 Jun 15;20(1):59. doi: 10.1186/s12944-021-01485-x. Lipids Health Dis. 2021. PMID: 34130693 Free PMC article.

3

Prediabetes Is Associated With Increased Liver Stiffness Identified by Noninvasive Liver Fibrosis Assessment: ElastPQ Ultrasound Shear Wave Elastography Study.

Koc AS, Sumbul HE. Koc AS, et al. Ultrasound Q. 2019 Dec;35(4):330-338. doi: 10.1097/RUQ.0000000000000419. Ultrasound Q. 2019. PMID: 30724873

4

Association of tissue inhibitor of metalloproteinase 2 with non-alcoholic fatty liver disease in metabolic syndrome.

Yasmeen S, Khan U, Khan GM, Fatima SS. Yasmeen S, et al. Arch Physiol Biochem. 2019 Dec;125(5):441-446. doi: 10.1080/13813455.2018.1481095. Epub 2018 Jun 18. Arch Physiol Biochem. 2019. PMID: 29912573

5

Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.

Hazem RM, Ibrahim AZ, Ali DA, Moustafa YM. Hazem RM, et al. Int Immunopharmacol. 2022 Mar;104:108503. doi: 10.1016/j.intimp.2021.108503. Epub 2022 Jan 5. Int Immunopharmacol. 2022. PMID: 34998036

6

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Cusi K, et al. J Hepatol. 2014 Jan;60(1):167-74. doi: 10.1016/j.jhep.2013.07.042. Epub 2013 Aug 20. J Hepatol. 2014. PMID: 23973932

7

Combined Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Sleeve Gastrectomy or Gastric Bypass?-a Controlled Matched Pair Study of 34 Patients.

Billeter AT, Senft J, Gotthardt D, Knefeli P, Nickel F, Schulte T, Fischer L, Nawroth PP, Büchler MW, Müller-Stich BP. Billeter AT, et al. Obes Surg. 2016 Aug;26(8):1867-74. doi: 10.1007/s11695-015-2006-y. Obes Surg. 2016. PMID: 26660688

8

Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo.

Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Williams KH, et al. Endocr Rev. 2013 Feb;34(1):84-129. doi: 10.1210/er.2012-1009. Epub 2012 Dec 13. Endocr Rev. 2013. PMID: 23238855 Review.

9

Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.

Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Bril F, et al. Hepatology. 2014 Jun;59(6):2178-87. doi: 10.1002/hep.26988. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24777953

10

[Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis].

Berlanga A, Guiu-Jurado E, Porras JA, Aragonès G, Auguet T. Berlanga A, et al. Clin Investig Arterioscler. 2016 Jan-Feb;28(1):47-61. doi: 10.1016/j.arteri.2015.03.003. Epub 2015 Jun 3. Clin Investig Arterioscler. 2016. PMID: 26049666 Review. Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results